

SUMO1 Antibody (N-term A6) Blocking Peptide
Synthetic peptide
Catalog # BP1222c**Specification**

SUMO1 Antibody (N-term A6) Blocking Peptide - Product InformationPrimary Accession [P63165](#)**SUMO1 Antibody (N-term A6) Blocking Peptide - Additional Information**

Gene ID 7341

Other Names

Small ubiquitin-related modifier 1, SUMO-1, GAP-modifying protein 1, GMP1, SMT3 homolog 3, Sentrin, Ubiquitin-homology domain protein PIC1, Ubiquitin-like protein SMT3C, Smt3C, Ubiquitin-like protein UBL1, SUMO1, SMT3C, SMT3H3, UBL1

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP1222c](/product/products/AP1222c) was selected from the N-term region of human SUMO1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SUMO1 Antibody (N-term A6) Blocking Peptide - Protein Information

Name SUMO1

Synonyms SMT3C, SMT3H3, UBL1

Function

Ubiquitin-like protein that can be covalently attached to proteins as a monomer or a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by E3 ligases such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Involved for instance in targeting RANGAP1 to the nuclear pore complex protein RANBP2. Covalently attached to the voltage-gated potassium channel KCNB1; this modulates the gating characteristics of KCNB1 (PubMed:19223394). Polymeric SUMO1 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins. May also regulate a network of genes involved in palate development. Covalently attached to ZFH3 (PubMed:24651376).

Cellular Location

Nucleus membrane. Nucleus speckle {ECO:0000250|UniProtKB:P63166}. Cytoplasm. Nucleus, PML body. Cell membrane. Nucleus. Note=Recruited by BCL11A into the nuclear body (By similarity). In the presence of ZFH3, sequestered to nuclear body (NB)-like dots in the nucleus some of which overlap or closely associate with PML body (PubMed:24651376) {ECO:0000250|UniProtKB:P63166, ECO:0000269|PubMed:24651376}

SUMO1 Antibody (N-term A6) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

SUMO1 Antibody (N-term A6) Blocking Peptide - Images

SUMO1 Antibody (N-term A6) Blocking Peptide - Background

Covalent attachment of one protein to another is one of the more prominent posttranslational modifications in respects to size and ubiquity ? to which eukaryotic proteins are subject. Ubiquitin is the most familiar of the protein modifiers and its activation and transfer to target proteins has been studied for over two decades. Recently a new group of ubiquitin-like (Ubl) proteins have come to light. One of the most intriguing of them is SUMO (small ubiquitin-like modifier, ~12kDa) also known as Sentrin. SUMO family has been described in vertebrates: SUMO-1 and the closest homologs SUMO-2 and SUMO-3. SUMO have been shown to bind and regulate mammalian SP-RINGS (such as Mdm2, PIAS and PML), RanGAP1, RanBP2, p53, p73, HIPK2, TEL, c-Jun, Fas, Daxx, TNFRI, Topo-I, Topo-II, WRN, Sp100, Ikb-alpha, Androgen receptor (AR), GLUT1/4, Drosophila Ttk69, Dorsal, CaMK, yeast Septins, and viral CMV-IE1/2, EBV-BZLF1, HPV/BPV-E1. These bindings implicate SUMO in the stabilization of the target proteins and/or their localization to subcellular complexes. SUMO research enters now an exciting phase with a promise to help understanding how cells orchestrate the complexities of rapidly regulating protein level and activity.

SUMO1 Antibody (N-term A6) Blocking Peptide - References

Yang, S.H., et al., Mol. Cell 13(4):611-617 (2004). Bailey, D., et al., J. Biol. Chem. 279(1):692-703 (2004). Ling, Y., et al., Nucleic Acids Res. 32(2):598-610 (2004). Pountney, D.L., et al., Exp. Neurol. 184(1):436-446 (2003). Ohshima, T., et al., J. Biol. Chem. 278(51):50833-50842 (2003).